Literature DB >> 24853275

Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Weiguang Xu1, Jung-Hee Kwon, Young Ho Moon, Young Bae Kim, Yun Suk Yu, Namgyu Lee, Kwan Yong Choi, Yun Soo Kim, Yong Keun Park, Bong Wan Kim, Hee Jung Wang.   

Abstract

PURPOSE: Although transcatheter arterial chemoembolization (TACE) is the most common treatment option in patients with hepatocellular carcinoma (HCC), its clinical benefits remain still controversial. Since TACE induces hypoxic necrosis in tumors, hypoxia-inducible factor 1α (HIF-1α) could critically affect biology in residual tumors after TACE treatment and subsequent prognosis. However, HIF-1α and its prognostic relevance in TACE have rarely been examined in human specimens. In the current study, we investigated the prognosis and expression of genes regulated by HIF-1α in HCC patients receiving preoperative TACE for the first time.
METHODS: In total, 35 patients with HCC (10 patients undergoing preoperative TACE) were retrospectively studied. The prognostic significance of TACE was analyzed using Kaplan-Meier and Cox regression models. Protein levels of HIF-1α and mRNA levels of HIF-1α-associated genes were examined using immunohistochemistry (IHC) and real-time RT-PCR, respectively.
RESULTS: Preoperative TACE was significantly associated with increased 2-year recurrence rate (80 vs. 36 %, P = 0.00402) and shorter disease-free survival (DFS) time (11.9 vs. 35.7 months, P = 0.0182). TACE was an independent prognostic factor for recurrence (P = 0.007) and poor DFS (P = 0.010) in a multivariate analysis. Immunohistochemical staining revealed in vivo activation of HIF-1α in human specimens treated with TACE. Notably, protein levels of HIF-1α were significantly increased in TACE tissues demonstrated by IHC. Transcriptional targets of HIF-1α showed mRNA expression patterns consistent with activation of HIF-1α in TACE tissues.
CONCLUSIONS: Our findings collectively demonstrate that preoperative TACE confers poor prognosis in HCC patients through activation of HIF-1α.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24853275     DOI: 10.1007/s00432-014-1713-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

Review 1.  Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.

Authors:  Riccardo Lencioni
Journal:  Crit Rev Oncol Hematol       Date:  2011-12-03       Impact factor: 6.312

2.  Targeted genes and interacting proteins of hypoxia inducible factor-1.

Authors:  Wei Liu; Shao-Ming Shen; Xu-Yun Zhao; Guo-Qiang Chen
Journal:  Int J Biochem Mol Biol       Date:  2012-05-31

3.  Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma.

Authors:  A Sasaki; Y Iwashita; K Shibata; M Ohta; S Kitano; M Mori
Journal:  Eur J Surg Oncol       Date:  2006-06-21       Impact factor: 4.424

4.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

5.  Preoperative transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Yoji Kishi; Akio Saiura; Junji Yamamoto; Rintaro Koga; Makoto Seki; Ryo Morimura; Ryuji Yoshioka; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Hepatogastroenterology       Date:  2012-10

6.  Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?

Authors:  T Harada; K Matsuo; T Inoue; S Tamesue; T Inoue; H Nakamura
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

7.  Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.

Authors:  Sameer H Patel; Peter J Kneuertz; Maria Delgado; David A Kooby; Charles A Staley; Bassel F El-Rayes; John S Kauh; Juan M Sarmiento; Steven Hanish; Cynthia Cohen; Alton B Farris; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2011-05-18       Impact factor: 5.344

8.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.

Authors:  Xin Li; Gan-Sheng Feng; Chuan-Sheng Zheng; Chen-Kai Zhuo; Xi Liu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

9.  The effect of preoperative transarterial chemoembolization of resectable hepatocellular carcinoma on clinical and economic outcomes.

Authors:  King-Teh Lee; Yi-Wei Lu; Shen-Nien Wang; Hong-Yaw Chen; Shih-Chang Chuang; Wen-Tsan Chang; Hon-Yi Shi; Chen-Guo Ker; Herng-Chia Chiu
Journal:  J Surg Oncol       Date:  2009-05-01       Impact factor: 3.454

10.  Overexpression of MMP-9 and HIF-1α in Breast Cancer Cells under Hypoxic Conditions.

Authors:  Jae Young Choi; Yeon Soo Jang; Sun Young Min; Jeong Yoon Song
Journal:  J Breast Cancer       Date:  2011-06-18       Impact factor: 3.588

View more
  14 in total

1.  The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Authors:  Masataka Amisaki; Soichiro Honjo; Masaki Morimoto; Takehiko Hanaki; Yosuke Arai; Naruo Tokuyasu; Teruhisa Sakamoto; Yasufumi Ohuchi; Hiroaki Saito
Journal:  Yonago Acta Med       Date:  2016-12-26       Impact factor: 1.641

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

3.  Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma.

Authors:  Shin Hwang; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Dong-Hwan Jung; Gil-Chun Park; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2016-06-16       Impact factor: 3.452

4.  Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization.

Authors:  Zhi-Juan Wu; Yin-Fa Xie; Xu Chang; Lin Zhang; Hui-Yong Wu; Ji-Bing Liu; Jian-Xin Zhang; Peng Sun
Journal:  Med Sci Monit       Date:  2021-05-10

Review 5.  The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma.

Authors:  Kang Liu; Xu-Li Min; Juan Peng; Ke Yang; Lin Yang; Xiao-Ming Zhang
Journal:  J Clin Med Res       Date:  2016-02-27

6.  Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials.

Authors:  Tengfei Si; Yongjun Chen; Di Ma; Xiaoyong Gong; Kui Yang; Ruoyu Guan; Chenghong Peng
Journal:  Scand J Gastroenterol       Date:  2016-08-10       Impact factor: 2.423

7.  Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.

Authors:  Mingsheng Huang; Long Wang; Junwei Chen; Mingjun Bai; Churen Zhou; Sujuan Liu; Qu Lin
Journal:  Int J Oncol       Date:  2016-03-04       Impact factor: 5.650

8.  Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.

Authors:  Ken Liu; Xiang Zhang; Weiqi Xu; Jinbiao Chen; Jun Yu; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Clin Transl Gastroenterol       Date:  2017-06-15       Impact factor: 4.488

Review 9.  The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies.

Authors:  Lei Chang; Yitao Wang; Jibo Zhang; Tao Guo
Journal:  Oncotarget       Date:  2017-03-21

10.  Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation.

Authors:  Caroline I Davis; Xingxing Gu; Ryan M Kiefer; Martina Ralle; Terence P Gade; Donita C Brady
Journal:  Metallomics       Date:  2020-12-23       Impact factor: 4.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.